Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,336 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06019702RecruitingPhase 1
Personalized mRNA vaccine for advanced digestive cancers
This trial tests a personalized mRNA vaccine designed to target unique markers on your cancer cells. The vaccine is made just for you based on genetic testing of your tumor. It is for people with advanced digestive system cancers who have run out of standard options.
Hangzhou, ZhejiangAges 18–75 - NCT06026800RecruitingPhase 1
Personalized mRNA vaccine plus standard treatment for advanced digestive cancers
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) given alongside standard first-line treatment for advanced digestive system cancers. The vaccine is made specifically for your tumor's unique genetic changes (neoantigens) and aims to help your immune system fight the cancer more effectively.
Hangzhou, ZhejiangAges 18–75 - NCT06056115Recruiting
Tislelizumab for lung cancer with brain metastases
This trial tests a drug called tislelizumab for people with advanced lung adenocarcinoma that has spread to the brain but is not causing symptoms. It is for those who have not had prior treatment and whose tumors do not have certain gene changes.
Shijiazhuang, HebeiAges 18–75 - NCT06070740RecruitingPhase 2
Durvalumab Plus Chemo for Advanced Gastrointestinal NEC
This trial tests a combination of durvalumab (an immunotherapy drug) plus a chemotherapy called XELOX as the first treatment for advanced gastrointestinal neuroendocrine carcinoma (NEC). It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT05260671RecruitingPhase 2
Penpulimab plus cetuximab for advanced head and neck cancer
This trial studies penpulimab (an immune medicine) combined with cetuximab (an antibody drug) for recurrent or metastatic squamous cell head and neck cancer that cannot be treated with surgery or radiation. It aims to shrink tumors and improve survival in people whose tumor shows a specific immune marker (PD-L1).
Changchun, JilinAges 18–80 - NCT06092086RecruitingPhase 2
Lorlatinib for first-line treatment of ALK-positive lung cancer
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
Guangzhou, GuangdongAges 18 years+ - NCT06102928Recruiting
Anlotinib plus Aumolertinib for first-line treatment of advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Kunming, YunnanAges 18 years+ - NCT06102772Recruiting
Combination immunotherapy and targeted therapy for advanced gastric cancer
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06102785Recruiting
Fruquintinib plus TAS102 for advanced stomach cancer
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06102759Recruiting
Study of adebrelimab and fruquintinib plus chemo for advanced stomach cancer after PD-1 failure
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06121089Recruiting
Surgery for early-stage cecal cancer
This trial is testing different surgical approaches for people with cecal cancer that hasn't spread. The goal is to find the best treatment option for patients whose tumors are at a stage where surgery can be curative.
MoscowAges 18 years+ - NCT04428528Recruiting
Ultrasound-like pictures that track breast tumors during chemotherapy
This study uses a special light-based imaging scan to learn more about breast masses and how tumors may respond to chemotherapy before surgery. The scan is meant to help doctors better characterize tumors and potentially track treatment response.
Toronto, OntarioAges Any age - NCT06201065RecruitingPhase 3
Targeted therapy and immunotherapy for advanced liver cancer
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Guangzhou, GuangdongAges 18–75 - NCT06123494RecruitingPhase 3
A trial of SHR-A1811 for HER2-positive gastric cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT02925234RecruitingPhase 2
Basket trial of reused cancer drugs matched to tumor markers
This trial tests cancer drugs that are already approved for other cancers, chosen based on specific changes found in your tumor. It may help people whose cancer is growing despite standard treatment (or who no longer have standard options).
AlkmaarAges 18 years+ - NCT06182657Recruiting
Nasopharyngeal cancer response to induction chemotherapy
This study looks at how well nasopharyngeal cancer (NPC) responds to the first round of chemotherapy before other treatments. It aims to see if the amount of tumor shrinkage can help predict outcomes and guide future care for people with advanced NPC.
Nanchang, JiangxiAges 18 years+ - NCT06254690RecruitingPhase 2
Pyrotinib dosing study for HER2-positive advanced breast cancer
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
Nanjing, JiangsuAges 18–70 - NCT07863141RecruitingPhase 2
Maintenance therapy after first-line chemoimmunotherapy for advanced esophageal cancer
This study compares two maintenance treatments after initial chemotherapy plus immunotherapy for advanced esophageal squamous cell carcinoma. The goal is to see if adding anlotinib, a targeted drug that blocks blood vessel growth to tumors, to a PD-1 inhibitor is more effective than the PD-1 inhibitor alone.
Guangzhou, GuangdongAges 18–75 - NCT07860528Recruiting
High-dose brachytherapy for prostate cancer that has returned
This trial tests a type of radiation therapy called high-dose-rate brachytherapy, which is given to men whose prostate cancer has come back after their first treatment. It aims to control the cancer while keeping side effects low.
Benidorm, AlicanteAges 18 years+ - NCT06277024Recruiting
Combination therapy for advanced HER2-negative stomach cancer
This trial tests a combination of immunotherapy (candenizumab), a targeted therapy (lenvatinib), and chemotherapy (SOX regimen) for advanced HER2-negative stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatments.
Fuzhou, FujianAges 18–75 - NCT04817956RecruitingPhase 2
Precision-medicine treatment for advanced cancer in Norway
This Phase 2 trial tries to match people with advanced cancer to targeted treatments based on their tumor’s genetic results. It may help if standard cancer treatments are no longer working or aren’t available, and if a “target” in the tumor suggests a therapy that could work.
ÅlesundAges 16 years+ - NCT06219980RecruitingPhase 2
Radiation and immunotherapy before surgery for oral cancer
This trial tests combining radiation therapy with immunotherapy and chemotherapy before surgery for advanced oral or throat cancer. The goal is to see if this approach can shrink the tumor and improve treatment outcomes.
Guangzhou, GuangdongAges 18–70 - NCT05280314RecruitingPhase 2
Immunotherapy before and after surgery for stage III melanoma or throat cancer
This trial tests two immunotherapy medicines given before surgery and again after surgery to help control the cancer and improve outcomes. It studies people with resectable (operable) stage III melanoma or certain stage III/IVA throat cancers.
New Haven, ConnecticutAges 18 years+ - NCT06196788RecruitingPhase 2
Artery infusion chemo for advanced pancreatic cancer
This trial tests a treatment called transcatheter arterial infusion, where chemotherapy drugs are delivered directly to the tumor through a thin tube in an artery. It's for people with advanced pancreatic cancer who haven't had other treatments yet.
Shanghai, Shanghai MunicipalityAges 18–80
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,336 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.